Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma |
| |
| Authors: | M E Kaye D H Thamm K Weishaar J A Lawrence |
| |
| Affiliation: | 1. Department of Small Animal Medicine & Surgery, University of Georgia, College of Veterinary Medicine, Athens, GA, USA;2. The Animal Cancer Center, Veterinary Teaching Hospital, Colorado State University, Collins, CO, USA;3. Current address: Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, UK |
| |
| Abstract: | The goal of this study was to evaluate the anti‐tumour activity and toxicoses of vinorelbine as a palliative rescue therapy for dogs with primary urinary bladder carcinoma. Thirteen dogs refractory to prior chemotherapeutics and one dog naïve to chemotherapeutic treatment were enrolled. Vinorelbine (15 mg m?2 IV) was administered intravenously along with concurrent oral anti‐inflammatory drugs, if tolerated. A median of six doses of vinorelbine (range: 1–16) was administered. Two dogs (14%) had partial responses, and eight (57%) experienced stable disease. Subjective improvement in clinical signs was noted in 11 dogs (78%). Adverse events were mild and primarily haematological in nature. Median time to progression was 93 days (range: 20–239 days). Median survival time for all dogs was 187 days; median survival for 13 pre‐treated dogs was 207 days. Vinorelbine may have utility in the management of canine primary urinary bladder carcinoma and should be evaluated in a prospective study. |
| |
| Keywords: | canine oncology quality of life urogenital medicine |
|
|
